# DESCRIPTION

- introduce invention
- relate to prior art
- describe FK866
- motivate anti-tumoral efficacy
- summarize publications
- describe EP 1 348 434
- contrast with prior art
- define inflammatory diseases
- describe cytokines
- motivate inhibition of cytokines
- describe unexpected anti-inflammatory properties
- establish functional link
- define embodiments
- define terms
- define rheumatoid arthritis
- define effective amount
- define nicotinamide phosphoribosyltransferase
- define nicotinic acid
- define TNF
- describe physiologically acceptable carrier
- describe benefits of the present invention
- describe implications for treatment strategies
- introduce first aspect of the present invention
- describe inhibitor of nicotinamide adenyl dinucleotide
- describe formula (I)
- describe R¹
- describe R²
- describe R³
- describe R⁴
- describe k
- describe A
- describe D
- describe E
- describe G
- describe G1
- describe G2
- describe G3
- describe G4
- describe G5
- describe preferred embodiment
- describe R¹ in preferred embodiment
- describe R² in preferred embodiment
- describe R³ in preferred embodiment
- describe R⁴ in preferred embodiment
- describe A in preferred embodiment
- define compound of formula (I)
- specify substituents for R¹, R², R³, R⁴, k, A, D, E, G
- specify substituents for R¹², R¹³, R¹⁴
- specify optional substituents for aromatic ring systems
- specify further preferred embodiment for R¹, R², R³, R⁴, k, A, D, E, G
- specify substituents for R¹², R¹³, R¹⁴ in further preferred embodiment
- specify optional substituents for aromatic ring systems in further preferred embodiment
- specify especially preferred embodiment for R¹, R², R³, R⁴, k, A, D, E, G
- specify substituents for R¹², R¹³, R¹⁴ in especially preferred embodiment
- specify optional substituents for aromatic ring systems in especially preferred embodiment
- list exemplary compounds
- describe synthesis methods
- specify use of inhibitor for treating rheumatoid arthritis
- specify use of (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyrid
- specify use of inhibitor for treating endotoxemia
- specify use of (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyrid
- describe structure of G1
- describe structure of G3
- describe optional substituents for heterocyclic ring
- describe optional substituents for aromatic ring systems
- describe optional formation of additional ring
- describe optional substituents for R¹⁴
- describe optional substituents for NR¹²R¹⁴
- describe optional substituents for aromatic ring systems
- describe optional formation of additional ring
- describe optional substituents for R¹⁴
- relate invention to medicament manufacturing process
- define inhibitor of nicotinamide adenyl dinucleotide formation
- specify preferred inhibitor compounds
- describe medicament embodiments for treating diseases
- outline administration and dosage of inhibitor
- prepare galenic composition with pharmaceutical carrier
- describe oral dosage forms and preparation
- describe parenteral administration forms and preparation
- outline pharmaceutical kit composition and instructions
- specify kit embodiments for treating diseases
- describe method of treating inflammatory diseases
- specify method embodiments for treating diseases
- provide experimental details and claims

## EXAMPLES

### Example 1

- illustrate relationship between NAD levels and pro-inflammatory cytokine secretion

### Example 2

- describe inhibition of pro-inflammatory cytokines production by FK866

### Example 3

- illustrate inhibition of TNFα secretion at posttranscriptional level

### Example 4

- describe inhibition of other pro-inflammatory cytokine production by FK866

### Example 5

- illustrate correlation between pro-inflammatory cytokine secretion and NAD levels
- show inhibition of TNF production correlates with inhibition of intracellular NAD levels
- demonstrate direct relationship between NAD levels and pro-inflammatory cytokine secretion

### Example 6

- illustrate inhibition of pro-inflammatory cytokine secretion is not due to apoptosis induction

### Example 7

- illustrate NAMPT is the only molecular target of FK866

### Example 8

- describe reduction of disease severity of rheumatoid arthritis in mouse model
- show FK866 ameliorates symptoms of arthritis

### Example 9

- describe upregulation of NAMPT expression in collagen-induced arthritis
- show NAMPT expression in sera and paw tissue extracts
- illustrate NAMPT immunohistochemistry
- describe NAMPT staining in arthritic paw and knee joints
- show NAMPT staining in synoviocytes and inflammatory cells
- illustrate NAMPT staining in blood vessels and chondrocytes
- describe NAMPT expression in normal and arthritic joints
- show NAMPT expression in CIA
- illustrate NAMPT expression in synovial lining layer and pannus
- describe NAMPT expression in sub-intimal synovium

